At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 52 target
Drug / intervention
BL-B01D1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody Combination Therapy in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 and PD-1 Monoclonal Antibody for Triple-negative Breast Cancer. Currently recruiting, targeting 52 participants across 1 site.
Detailed Summary
This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-negative Breast Cancer
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2RecruitingOverdue
20252026
First PostedJun 2024
Enrollment StartAug 2024
Primary CompletionJul 2026
TodayJul 2026
First PostedJun 24, 2024
Enrollment StartAug 2, 2024
Primary CompletionJul 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 2.0 years ago
Interventions
BL-B01D1drug
Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.
PD-1 Monoclonal Antibodydrug
Administration by intravenous infusion for a cycle of 3 weeks (Q3W).